Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
20
|
pubmed:dateCreated |
1991-8-19
|
pubmed:abstractText |
The stilbene disulfonic acids 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), 4,4'-diisothiocyanatodihydrostilbene-2,2'-disulfonic acid and, 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid bound the variable-1 immunoglobulin-like domain of CD4 on JM cells. The interaction blocked the binding of the anti-CD4 monoclonal antibody OKT4A and the envelope glycoprotein gp120 of the human immunodeficiency virus type-1 (HIV-1). DIDS inhibited the acute infection of CD4+ cells by HIV-1 with a potency (IC50 approximately 30 microM) similar to that which blocked gp120 binding (IC50 approximately 20 microM) to the cellular antigen. Pretreating uninfected CD4+ C8166 cells with DIDS blocked their fusion with chronically infected gp120+ cells. DIDS covalently and selectively modified lysine 90 of soluble CD4 and abolished the gp120-binding and antiviral properties of the recombinant protein. When added to cells productively infected with HIV-1, DIDS blocked virus growth and cleared cultures of syncytia without inhibiting cellular proliferation. The stilbene disulfonic acids are a novel class of site-specific CD4 antagonists that block multiple CD4-dependent events associated with acute and established HIV-1 infections.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4,4'-Diisothiocyanostilbene-2,2'-Dis...,
http://linkedlifedata.com/resource/pubmed/chemical/4-Acetamido-4'-isothiocyanatostilben...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp120,
http://linkedlifedata.com/resource/pubmed/chemical/dihydro-DIDS
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
266
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
13355-63
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:2071607-4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid,
pubmed-meshheading:2071607-4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid,
pubmed-meshheading:2071607-Animals,
pubmed-meshheading:2071607-Antigens, CD4,
pubmed-meshheading:2071607-Antiviral Agents,
pubmed-meshheading:2071607-Cell Line,
pubmed-meshheading:2071607-HIV Envelope Protein gp120,
pubmed-meshheading:2071607-HIV-1,
pubmed-meshheading:2071607-Humans,
pubmed-meshheading:2071607-Molecular Structure,
pubmed-meshheading:2071607-Structure-Activity Relationship,
pubmed-meshheading:2071607-T-Lymphocytes
|
pubmed:year |
1991
|
pubmed:articleTitle |
Stilbene disulfonic acids. CD4 antagonists that block human immunodeficiency virus type-1 growth at multiple stages of the virus life cycle.
|
pubmed:affiliation |
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.
|
pubmed:publicationType |
Journal Article
|